{"transactions":[{"id":732121,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:08:42.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":57100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":264254,"source":{"system":"sec-edgar","filing":"0001838042-26-000003","document":"wk-form4_1781813319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000183804226000003/wk-form4_1781813319.xml","form_type":"4"}},{"id":739042,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:05:11.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":25800,"derivative":{"exercise_price":17.1,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25800},"source":{"system":"sec-edgar","filing":"0001193125-26-269378","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526269378/ownership.xml","form_type":"4"}},{"id":1106357,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T20:17:03.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":57603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":207154,"source":{"system":"sec-edgar","filing":"0001725160-25-000135","document":"wk-form4_1750277814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000135/wk-form4_1750277814.xml","form_type":"4"}},{"id":1109329,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:04.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":30700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":30700,"derivative":{"exercise_price":4.91,"expiration_date":"2035-06-13","underlying":"Common Stock","underlying_shares":30700},"source":{"system":"sec-edgar","filing":"0000950170-25-086700","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017025086700/ownership.xml","form_type":"4"}},{"id":1284941,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T21:45:00.000Z","date":"2025-01-31","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":1.7241,"value":103446.0,"ownership":{"direct":true},"balance_after":149551,"source":{"system":"sec-edgar","filing":"0001725160-25-000030","document":"wk-form4_1738705494.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000030/wk-form4_1738705494.xml","form_type":"4"}},{"id":1472111,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T21:11:02.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":41581,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":89551,"source":{"system":"sec-edgar","filing":"0001725160-24-000145","document":"wk-form4_1719004255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000145/wk-form4_1719004255.xml","form_type":"4"}},{"id":1480133,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-13T20:30:12.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":22100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":22100,"derivative":{"exercise_price":4.16,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":22100},"source":{"system":"sec-edgar","filing":"0000950170-24-073063","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024073063/ownership.xml","form_type":"4"}},{"id":1782108,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-13T20:11:17.000Z","date":"2023-09-11","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":25.0475,"value":125237.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires September 14, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.76 to $25.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47970,"source":{"system":"sec-edgar","filing":"0001725160-23-000162","document":"wk-form4_1694635867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000162/wk-form4_1694635867.xml","form_type":"4"}},{"id":1852369,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T21:01:25.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":16364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":52970,"source":{"system":"sec-edgar","filing":"0001725160-23-000141","document":"wk-form4_1686949276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000141/wk-form4_1686949276.xml","form_type":"4"}},{"id":1853727,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T20:29:19.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":20500,"derivative":{"exercise_price":6.59,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-23-037355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000120919123037355/doc4.xml","form_type":"4"}},{"id":1933690,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-31T20:15:14.000Z","date":"2023-03-30","kind":"grant","planned":false,"acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 36 substantially equal monthly installments following the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":41000,"derivative":{"exercise_price":7.36,"expiration_date":"2033-03-29","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001209191-23-021859","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000120919123021859/doc4.xml","form_type":"4"}},{"id":2161295,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-12T11:07:52.000Z","date":"2022-09-09","kind":"grant","acquired":true,"shares":36606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (\"RSUs\") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program.  One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":36606,"source":{"system":"sec-edgar","filing":"0001725160-22-000165","document":"wf-form4_166298085835189.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516022000165/wf-form4_166298085835189.xml","form_type":"4"}},{"id":2502207,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:20:57.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":12.03,"expiration_date":"2030-12-23","underlying":"Common Shares","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001104659-21-141737","document":"tm2133436d14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141737/tm2133436d14_4seq1.xml","form_type":"4"}},{"id":2502206,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:20:57.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":1162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":0.427,"expiration_date":"2029-09-25","underlying":"Common Shares","underlying_shares":1162500},"source":{"system":"sec-edgar","filing":"0001104659-21-141737","document":"tm2133436d14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141737/tm2133436d14_4seq1.xml","form_type":"4"}},{"id":2502205,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:20:57.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":197000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":0.3,"expiration_date":"2029-11-07","underlying":"Common Shares","underlying_shares":197000},"source":{"system":"sec-edgar","filing":"0001104659-21-141737","document":"tm2133436d14_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141737/tm2133436d14_4seq1.xml","form_type":"4"}},{"id":2713915,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-13T16:12:45.000Z","date":"2021-05-12","kind":"exercise","acquired":false,"shares":23802,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months."}],"balance_after":197000,"derivative":{"exercise_price":0.314,"expiration_date":"2029-11-07","underlying":"Common Shares","underlying_shares":23802},"source":{"system":"sec-edgar","filing":"0001062993-21-004511","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321004511/form4.xml","form_type":"4"}},{"id":2713914,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-13T16:12:45.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":19198,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months."}],"balance_after":220802,"derivative":{"exercise_price":0.314,"expiration_date":"2029-11-07","underlying":"Common Shares","underlying_shares":19198},"source":{"system":"sec-edgar","filing":"0001062993-21-004511","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321004511/form4.xml","form_type":"4"}},{"id":2713913,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-13T16:12:45.000Z","date":"2021-05-11","kind":"exercise","acquired":false,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months."}],"balance_after":1162500,"derivative":{"exercise_price":0.4462,"expiration_date":"2029-09-25","underlying":"Common Shares","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001062993-21-004511","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321004511/form4.xml","form_type":"4"}},{"id":2713912,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2021-05-13T16:12:45.000Z","date":"2021-05-12","kind":"sale","acquired":false,"shares":23802,"price":9.2379,"value":219880.4958,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.20 to $9.25 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-21-004511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321004511/form4.xml","form_type":"4"}},{"id":2713911,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2021-05-13T16:12:45.000Z","date":"2021-05-12","kind":"exercise","acquired":true,"shares":23802,"price":0.314,"value":7473.828,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD."}],"balance_after":23802,"source":{"system":"sec-edgar","filing":"0001062993-21-004511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321004511/form4.xml","form_type":"4"}},{"id":2713910,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2021-05-13T16:12:45.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":106698,"price":9.2017,"value":981802.9866,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.12 to $9.36 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-21-004511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321004511/form4.xml","form_type":"4"}},{"id":2713909,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2021-05-13T16:12:45.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":19198,"price":0.314,"value":6028.172,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD."}],"balance_after":106698,"source":{"system":"sec-edgar","filing":"0001062993-21-004511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321004511/form4.xml","form_type":"4"}},{"id":2713908,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2021-05-13T16:12:45.000Z","date":"2021-05-11","kind":"exercise","acquired":true,"shares":87500,"price":0.4462,"value":39042.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8263 USD."}],"balance_after":87500,"source":{"system":"sec-edgar","filing":"0001062993-21-004511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321004511/form4.xml","form_type":"4"}},{"id":2905546,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-15T16:19:10.000Z","date":"2021-01-14","kind":"exercise","acquired":false,"shares":19581,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7916 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months."}],"balance_after":1250000,"derivative":{"exercise_price":0.4275,"expiration_date":"2029-09-25","underlying":"Common Shares","underlying_shares":19581},"source":{"system":"sec-edgar","filing":"0001062993-21-000396","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321000396/form4.xml","form_type":"4"}},{"id":2905545,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-15T16:19:10.000Z","date":"2021-01-13","kind":"exercise","acquired":false,"shares":5419,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7867 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months."}],"balance_after":1269581,"derivative":{"exercise_price":0.4248,"expiration_date":"2029-09-25","underlying":"Common Shares","underlying_shares":5419},"source":{"system":"sec-edgar","filing":"0001062993-21-000396","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321000396/form4.xml","form_type":"4"}},{"id":2905544,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2021-01-15T16:19:10.000Z","date":"2021-01-14","kind":"sale","acquired":false,"shares":19581,"price":15.0288,"value":294278.9328,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-21-000396","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321000396/form4.xml","form_type":"4"}},{"id":2905543,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2021-01-15T16:19:10.000Z","date":"2021-01-14","kind":"exercise","acquired":true,"shares":19581,"price":0.4275,"value":8370.8775,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7916 USD."}],"balance_after":19581,"source":{"system":"sec-edgar","filing":"0001062993-21-000396","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321000396/form4.xml","form_type":"4"}},{"id":2905542,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2021-01-15T16:19:10.000Z","date":"2021-01-13","kind":"sale","acquired":false,"shares":5419,"price":15.0411,"value":81507.7209,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-21-000396","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321000396/form4.xml","form_type":"4"}},{"id":2905541,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Shares","published_at":"2021-01-15T16:19:10.000Z","date":"2021-01-13","kind":"exercise","acquired":true,"shares":5419,"price":0.4248,"value":2301.9912,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7867 USD."}],"balance_after":5419,"source":{"system":"sec-edgar","filing":"0001062993-21-000396","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321000396/form4.xml","form_type":"4"}}]}